Drug–drug interactions between epidermal growth factor receptor tyrosine kinase inhibitors and rivaroxaban in vitro and in vivo
These findings confirm the presence of DDIs between EGFR TKIs and rivaroxaban. Avitinib and gefitinib significantly inhibit rivaroxaban metabolism, and their co-administration may aggravate the risk of bleeding.
Authors
- Peiwu Geng (ORCID: https://orcid.org/0000-0002-9714-7660)
- Shuanghu Wang (ORCID: https://orcid.org/0000-0002-0057-267X)
- Jiefu Yang (ORCID: https://orcid.org/0000-0002-2273-4860)
- Da‐Peng Dai
- Hualan Wu
- Chuanbao Li (ORCID: https://orcid.org/0000-0002-1224-0509)
- Xiaoyue Zhou
- Fang Wang (ORCID: https://orcid.org/0000-0002-6674-5537)
- Zebei Lu
- Hao Chen (ORCID: https://orcid.org/0000-0003-3074-2235)
- Dongxu Wang (ORCID: https://orcid.org/0009-0007-5189-0348)
- Yingying Li (ORCID: https://orcid.org/0009-0004-0817-8329)
- Yu Wang (ORCID: https://orcid.org/0000-0003-2265-3742)
- Yang An (ORCID: https://orcid.org/0000-0002-3312-7265)
- Minghui Du (ORCID: https://orcid.org/0000-0001-7288-8174)
- Jia Wen Chong
- Yuwei Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Geriatric Hospital (CN)
- Lishui Central Hospital (CN)
- Beijing Hospital (CN)
- Lishui City People's Hospital (CN)
- Fu Wai Hospital (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1371/journal.pone.0322303
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Zhejiang Province Public Welfare Technology Application Research Project